Researchers funded by the National Institutes of Health (NIH) have identified a new immune disorder--DOCK2 deficiency--named after the mutated gene responsible for the disease. An international team of collaborators studied five children, four boys and one girl, from different ethnic backgrounds who had experienced debilitating infections early in life. The children were diagnosed with combined immunodeficiency (CID), which refers to a group of inherited disorders distinguished by defects in immune system cells called T cells. CIDs also may affect other cells of the immune system, including B cells.
By sequencing the children's genomes, the researchers discovered that mutations in a gene called DOCK2 ultimately cause this particular CID. In laboratory tests, T cells and B cells from the five children had impaired ability to move in response to infection-related stimuli, and anti-viral responses were impaired in many cell types. These observations highlight the importance of DOCK2 in a healthy immune system, and understanding its role may inform the study of more common immune system disorders and the body's response to infection, according to the study investigators.
Three of the children were successfully treated with bone marrow transplants, which replaced the defective immune cells with those of a healthy donor. This finding demonstrates that early screening for CID to identify patients with DOCK2 deficiency can potentially prevent life-threatening infection early in life, as it did for one of these children, who was screened for severe combined immune deficiency (SCID) at birth. Furthermore, identifying causative genes underlying CIDs, such as DOCK2, may enable researchers to develop targeted therapies.
The study was funded by NIH's National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences, as well as other programs. The research, conducted by investigators from several institutions, was led by Boston Children's Hospital, Rockefeller University, and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences.
Dobbs K, Conde CD, Zhang SY, Parolini S et al. Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections. New England Journal of Medicine DOI: 10.1056/NEJMoa1413462 (2015).
David Johnson, Ph.D., of the Rheumatologic Autoimmune Disease Section in NIAID's Division of Allergy, Immunology and Transplantation, is available to discuss the findings.
To schedule interviews, contact Linda Huynh, (301) 402-1663, firstname.lastname@example.org.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH):
NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.